MedTrace Logo

Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body

NCT00800280 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2010-02-17

No results posted yet for this study

Summary

The purpose of this study is to estimate the effects of multiple doses of cimetidine on the pharmacokinetics of a single dose of PD 0332334 and to evaluate the safety and tolerability of PD 0332334 when co-administered with cimetidine.

Conditions

  • Generalized Anxiety Disorder

Interventions

DRUG

PD 0332334

Single 300 mg dose of PD 0332334 immediate release capsules administered orally

DRUG

PD 0332334

Single 300 mg dose of PD 0332334 immediate release capsules administered orally on Day 2.

DRUG

cimetidine

600 mg q 6 hours cimetidine immediate release formulation administered orally on Days 1 through 5.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00800280 on ClinicalTrials.gov